section name header

Interacting Drugs

OBJECT DRUGS

PRECIPITANT DRUGS

Enzyme Inhibitors:


Comment:

These drugs inhibit CYP2D6, and can lead to accumulation of eliglusatat, with increased risk of eliglustat toxicity. Since eliglustat is also metabolized by CYP3A4, the risk of eliglustat toxicity from concurrent CYP2D6 inhibitors is likely to be greater in patients also receiving CYP3A4 inhibitors. (See CYP Table) The eliglustat label states that concurrent use of CYP2D6 inhibitors and CYP3A4 inhibitors is contraindicated in patients taking eliglustat.


Class 2: Use Only if Benefit Felt to Outweigh Risk